

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Patent Application of

Avraham Cohen et al.

Application No.: 10/561,844

Filing Date: December 22, 2005

Title: MONOHYDRATED SODIUM SALT OF
S-TENATOPRAZOLE AND THE USE
THEREOF IN THERAPY



Group Art Unit:

Examiner:

Confirmation No.: 5513

FIRST
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a FIRST Information Disclosure Statement (IDS) and accompanying form PTO-1449 for the above-identified patent application.


- No additional fee for submission of an IDS is required.
- The fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e), and the fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- Charge _____ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of _____ is enclosed for the fee due.
- Charge _____ to credit card for the fee due. Form PTO-2038 is attached.
- The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date February 5, 2007

By:


Melissa M. Hayworth
Registration No. 45774

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Avraham Cohen et al.

Application No.: 10/561,844

Filed: December 22, 2005

For: MONOHYDRATED SODIUM SALT OF
S-TENATOPRAZOLE AND THE USE
THEREOF IN THERAPY



) Group Art Unit:

) Examiner:

) Confirmation No.: 5513

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

A copy of the International Search Report mailed 30 November 2005 from the corresponding PCT application is enclosed.


To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. § 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No.02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: February 5, 2007

By: 
Melissa M. Hayworth
Registration No. 45774

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

**FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number

10/561,844

Filing Date

December 22, 2005

First Named Inventor

Avraham COHEN

Examiner Name

1. *What is the primary purpose of the study?*

Sheet 1 of 1

Attorney Docket Number

1032013-000133

FEB 05 2007

• 18 2007

RTB 18

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Bunpei Kakinoki et al. "General Pharmacological Properties of the New Proton Pump Inhibitor (+)-5-Methoxy-2-[(4-methoxy-3, 5-dimethylpyrid-2-yl)methyl]sulfinyl]-1 <i>H</i> -imidazo[4,5- <i>b</i>]pyridine", Vol. 21, No. 3, 1999, pgs. 179-187.
	International Search Reported dated 30 November 2005

Examiner Signature	/Niloofar Rahmani/	Date Considered	04/01/2008
-----------------------	--------------------	--------------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/